2013
DOI: 10.1530/endoabs.32.p982
|View full text |Cite
|
Sign up to set email alerts
|

PRIMARA: a prospective descriptive observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0
5

Year Published

2015
2015
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(18 citation statements)
references
References 0 publications
0
13
0
5
Order By: Relevance
“…24 Recently, cinacalcet, a calcimimetic agent, has been proved in a prospective observational study to be effective in lowering serum calcium levels in people with sporadic and familial primary hyperparathyroidism, but it has no effects on other features of primary hyperparathyroidism-that is, bone mineral density and hypercalciuria. 25 with primary hyperparathyroidism with specific indications. The EMA panel stated that cinacalcet can be an option in those where parathyroidectomy is indicated based on serum calcium levels but for whom surgery is otherwise "not clinically appropriate or contraindicated."…”
Section: Mild Hypercalcaemiamentioning
confidence: 99%
See 1 more Smart Citation
“…24 Recently, cinacalcet, a calcimimetic agent, has been proved in a prospective observational study to be effective in lowering serum calcium levels in people with sporadic and familial primary hyperparathyroidism, but it has no effects on other features of primary hyperparathyroidism-that is, bone mineral density and hypercalciuria. 25 with primary hyperparathyroidism with specific indications. The EMA panel stated that cinacalcet can be an option in those where parathyroidectomy is indicated based on serum calcium levels but for whom surgery is otherwise "not clinically appropriate or contraindicated."…”
Section: Mild Hypercalcaemiamentioning
confidence: 99%
“…Admission to hospital is required for people with severe hypercalcaemia (>3.5 mmol/L); emergency treatment includes aggressive intravenous hydration with 3-4 litres of 0.9% saline daily, or 1-2 litre bolus of 0.9% saline, followed by 200-250 mL saline hourly. 25 The rationale underlying hydration is that people with hypercalcaemia are often severely dehydrated, mainly because of nephrogenic diabetes insipidus due to hypercalcaemia and reduced water intake. The latter results from anorexia, nausea, and vomiting induced by the hypercalcaemia itself as well as the causative disease, such as neoplasia.…”
Section: Severe Hypercalcaemiamentioning
confidence: 99%
“…Long-term up to 5 years administration of cinacalcet is associated with a sustained control of hypercalcemia and PTH levels. However, changes in bone mineral density could not be detected [1][2][3][4][5][6][7][8][9][10].…”
Section: English Versionmentioning
confidence: 87%
“…L'administration du cinacalcet à long terme jusqu'à 5 ans s'associe à un contrôle durable de l'hypercalcémie et des taux de PTH. Toutefois, on ne peut mettre en évidence de changement de la densité minérale osseuse [1][2][3][4][5][6][7][8][9][10].…”
Section: Version Françaiseunclassified
“…Cinacalcet is a calcimimetic agent that activates the calcium sensing receptor (CaSR) on the surface of parathyroid glands. In addition to parathyroid cells, the CaSR is expressed along the nephron as well as in other tissues and is the regulator of PTH synthesis and secretion [85,86]. By increasing the sensitivity of the CaSR to extracellular calcium it effects a reduction in PTH and therefore a reduction in serum calcium level [87,88].…”
Section: Duration Of Actionmentioning
confidence: 99%